Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2016 - 2025)

Ultragenyx Pharmaceutical has reported Other Accumulated Expenses over the past 11 years, most recently at $24.0 million for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 500.0% to $24.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2025, up 500.0% year-over-year, with the annual reading at $24.0 million for FY2025, 500.0% up from the prior year.
  • Other Accumulated Expenses was $24.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $19.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $59.9 million in Q3 2022 and troughed at $2.6 million in Q2 2025.
  • The 5-year median for Other Accumulated Expenses is $32.2 million (2021), against an average of $34.1 million.
  • The largest YoY upside for Other Accumulated Expenses was 500.0% in 2025 against a maximum downside of 93.33% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $42.1 million in 2021, then rose by 23.99% to $52.2 million in 2022, then dropped by 2.64% to $50.8 million in 2023, then plummeted by 92.13% to $4.0 million in 2024, then surged by 500.0% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Accumulated Expenses are $24.0 million (Q4 2025), $19.0 million (Q3 2025), and $2.6 million (Q2 2025).